Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome

We report a pediatric patient with atypical hemolytic uremic syndrome due to a C3 gain-of-function mutation diagnosed in infancy. She was treated from the start with a constant dose of 300 mg eculizumab every second week from the onset and followed by routine complement analyses for six years. Her c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjerre, Anna, Bergseth, Grethe, Ludviksen, Judith Krey, Stokke, Arne, Bosnes, Vidar, Karpman, Diana, Mollnes, Tom Eirik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312603/
https://www.ncbi.nlm.nih.gov/pubmed/30662780
http://dx.doi.org/10.1155/2018/3810249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312603/
https://www.ncbi.nlm.nih.gov/pubmed/30662780
http://dx.doi.org/10.1155/2018/3810249

Ejemplares similares